Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 9/20 | 0.42 |
| ▸ | JAK3 | P52333 | 8/20 | 0.42 |
| ▸ | JAK1 | P23458 | 8/20 | 0.42 |
| ▸ | TYK2 | P29597 | 7/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719735 | 0.86 | KDM1A (0.47) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL31057999 | 0.84 | KDM1A (0.49) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL16423979 | 0.83 | ALDH1A1 (0.42) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL22468588 | 0.82 | ALDH1A1 (0.39) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL16424284 | 0.79 | ALDH1A1 (0.38) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1011800 | 0.78 | ALDH1A1 (0.51) | KDM1AALDH1A1HTTSMN1; SMN2RAF1 | |
| SCHEMBL573863 | 0.77 | JAK3 (0.45) | KDM1AJAK2JAK3JAK1TYK2 | |
| SCHEMBL11915943 | 0.76 | CRACR2A (0.41) | KDM1AJAK2JAK3JAK1TYK2 | |
| SCHEMBL4730942 | 0.76 | ALDH1A1 (0.64) | KDM1AALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL10982353 | 0.75 | KDM1A (0.37) | KDM1AHTTSMN1; SMN2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122134-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | KDM1A 382/4885ALDH1A1 1339/4885HTT 3231/4885 |
| US-20230192722-A1 | SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF | FGFR1, FGFR3, FGFR4 | KDM1A 391/4885ALDH1A1 1054/4885HTT 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.